Kissei introduces Iktos AI Drug Discovery System

Our Portfolio company, Iktos announced that Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs, has introduced Makya™, Iktos Software as a Service Platform for AI-driven drug discovery. This will enable the rapid and efficient design of new small molecules, leading to an increase in the speed of drug discovery and development.

At Iktos, we strive to build an innovative technology platform capable of improving the efficiency of small molecule discovery by combining our powerful algorithmic technology, our know-how derived from the experience of the many collaborations we have established to date, and an intuitive and user-friendly user interface which is essential to an optimal user experience.

said Yann Gaston-Mathé, Co-founder and CEO of Iktos.

Click here to access their full press release